Announcement • Jun 02
Allurion Technologies Announces Launch of Allurion Program in United States with Strong Early Outcomes Allurion Technologies Inc. announced successful early traction in the launch of the Allurion Program in the United States, marked by strong clinical outcomes, rapid account growth, high re-order rates, and performance exceeding internal expectations. First shipments of the Allurion Smart Capsule were completed in April, with the first U.S. patients treated that same month. Early clinical outcomes have been highly encouraging, with patients losing between 8–11% of their total body weight in just the first four weeks, reinforcing the program’s potential to deliver rapid, meaningful weight loss without surgery or invasive procedures. Of note, nearly all patients treated to date in the U.S. had previously tried a GLP-1 medication and ultimately discontinued. Commercial momentum in the U.S. has accelerated rapidly. In the largest obesity market in the world, the company is on track to grow two-fold within the quarter, while the number of treatment sessions is expected to increase four-fold, reflecting strong provider demand and increasing patient flow. Notably, early adoption in the U.S. is exceeding internal expectations for the quarter during just the second month of launch with key business metrics also outperforming plan: Re-order rates robust, with over half of quarterly business coming from re-ordering accounts; Average Selling Price (ASP) tracking ahead of expectations; Gross margins exceeding internal targets, with the first quarter of U.S. launch expected to be profitable; Strong pipeline, with the number of accounts trained or currently in training already in line with full-year goals. This re-order dynamic highlights rapid account adoption and early profitability for providers, signaling strong product-market fit in the U.S. obesity care landscape. Physicians across early adopter sites are reporting both strong patient outcomes and compelling economics. Allurion’s U.S. launch is resonating with a large and underserved patient segment—those who have previously tried GLP-1 medications but discontinued treatment. The Allurion Program is a weight-loss platform that combines the FDA PMA approved Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers featuring the Iris AI platform, Allurion Insights for healthcare providers, and the Allurion Connected Scale. In the United States, the Allurion Gastric Balloon System (AGBS) is indicated to promote short-term limited weight loss in adult individuals with obesity between the ages of 22 years and 65 years with a body mass index (BMI) = 30 kg/m2 and = 40 kg/m2 who have had at least one unsuccessful attempt at a weight loss program. The residence time for each balloon is variable with an average observed residence time of 15.3 weeks. The AGBS is to be used in conjunction with a moderate intensity lifestyle modification therapy program. The AGBS consists of up to two Allurion Balloons placed during a 10-month period. Announcement • Apr 21
Allurion Technologies, Inc. Treats First Commercial Patients In United States With Allurion Program Allurion Technologies Inc. announced the successful commercial treatment of its first patients in the United States—an inflection point that formally launches the company into the world’s largest and most dynamic obesity market. Allurion is seeing growing demand from patients who have discontinued GLP-1 therapy due to side effects, long-term commitment concerns, or weight regain following discontinuation. These early patient profiles reinforce Allurion’s positioning as a compelling, non-surgical, non-pharmaceutical option that delivers fast weight loss results within the rapidly evolving obesity treatment landscape. Early feedback from trained centers has been highly encouraging, underscoring the differentiated value of the Allurion Program, especially among patients who are searching for alternatives to GLP-1 medications. Clinicians have highlighted the Program’s simplicity and scalability as a competitive advantage, with the entire placement taking only about 15 minutes and requiring no endoscopy or anesthesia. In addition to its growing network of clinical partners, Allurion also announced that it is actively exploring partnerships with self-insured employers. These initiatives aim to substantially expand the pool of patients who can access the Allurion Smart Capsule through employer-sponsored coverage, while helping employers address the rising health and productivity costs associated with obesity. Announcement • Mar 13
Allurion Advances Plan to Regain Listing Compliance Allurion Technologies Inc. announced that it has appealed the decision by the New York Stock Exchange (the “NYSE”) to initiate delisting proceedings against Allurion’s securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual, which requires listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The Company’s recent FDA approval of the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, catalyzed a detailed plan to regain compliance with NYSE listing standards or to relist its securities on the NYSE American, strengthen its balance sheet, and fund commercialization of the Allurion Smart Capsule in the U.S. This plan has been shared with the NYSE and is currently being executed by the Company’s management. “We have been in regular contact with the NYSE about our step-by-step plan to regain compliance with its listing standards or initiate listing on the NYSE American,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “The first step in our plan was receiving FDA approval, which was received on February 20, 2026. We are leveraging this approval to touch off the remaining parts of our plan to ultimately regain compliance or relist. “We are confident we can execute this plan, setting up Allurion to capitalize on our U.S. FDA approval and enabling us to treat the more than 100 million Americans suffering from obesity, 20 million of whom have already tried a GLP-1 but discontinued use,” Dr. Gaur concluded. While the Company has appealed the NYSE’s decision and is working diligently to regain compliance with the NYSE or relist on the NYSEA, there can be no assurance that these efforts will be successful. The Company’s securities are trading on the OTCID exchange while the Company works to execute its above-referenced plan. 
